(Nasdaq: JAGX) Aims For Market Disruption Through New Planned Use Of AI Platforms

Jaguar Health, Inc. (Nasdaq: JAGX) is on our radars first thing Monday morning.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: JAGX) Aims For Market Disruption Through New Planned Use Of AI Platforms *Click Here To Get Our Alerts Faster Via SMS* April 13th Greetings Readers, Jaguar Health, Inc. (Nasdaq: JAGX) is on our radars first thing Monday morning. And for good reason! Check out this news that just dropped: Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs Global Market for Short Bowel Syndrome, Including Intestinal Failure (IF), Estimated to Reach $8.0Bn by 2033 AI data mining of real world clinical and symptom manifestation is beneficial in the development of credible links between genetics, histopathology, and disease progression modification for intestinal failure (IF) patients with orphan disease designated pediatric microvillus inclusion disease (MVID) Jaguar seeking efficiencies to bring crofelemer to FDA approval for MVID-a disease with no alternative treatments and a lethal natural history SAN FRANCISCO, CA / ACCESS Newswire / April 13, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it plans to use AI platforms to enhance its development, commercialization, and heal-thcare delivery objectives for crofelemer programs for the treatment of intestinal failure in both adult and pediatric patients. "Our IF program in MVID could leverage AI platforms that could help guide personalized regimens for each patient for this ultrarare disease and include real-world evidence to support the effectiveness and benefit of new therapies like crofelemer in mitigating disease progression by potentially providing credible links between genetics, histopathology, and clinical manifestation. AI platforms could lead to more efficient drug development and quicker access to drugs for patients with no alternative treatments for diseases with lethal natural history, such as MVID," said Pravin Chaturvedi, PhD, Jaguar's Chief Scientific Officer and Chair of the Jaguar Scientific Advisory Board. "We are strategically focused on demonstrating crofelemer's effectiveness and achieving faster commercialization to meet our healthcare delivery objectives for IF indications," said Lisa Conte, Jaguar's founder, president, and CEO. "Our IF development programs continue to make progress in meeting key clinical milestones, including the ground-breaking and consistent reduction of parenteral support of up to 37% in an investigator-sponsored MVID treatment program. We are currently in business development discussions with the goal of bringing in non-dilutive funds from potential partners. We are encouraged to report that our development plan for MVID could include a plan for obtaining Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) in the coming months, which would augment expedited regulatory submission pathways for this pediatric disorder. The very low prevalence of MVID and its lethal natural history without any available therapies underscores the need for rapid and efficient development and commercialization of crofelemer. In addressing this very serious unmet medical need, and we are exploring AI platforms to assist in achieving our objectives." Read the full article here. On top of the news, it's important to note that JAGX is a low float idea. With just over 12Mn shares in its float, the potential for heightened volatility could follow JAGX on a daily basis. Spend a moment to review my initial (Nasdaq: JAGX) report below and consider this profile of your watchlist. ----- As medicine continues to evolve, one organization is stepping into specific gaps that global health has left unfilled. With its focus on novel therapies for challenging gastrointestinal disorders, it’s opening new paths toward improved outcomes for patients who have few alternatives. Guided by experts with deep experience in both clinical and translational science, the team blends disciplined research with a clear sense of purpose. Its latest breakthroughs mark it as a company worth attention from anyone tracking major shifts in health innovation. And with a low float just over 12Mn shares and recent announcement of net revenue growth from Q3 to Q4 2025, this under-the-radar Nasdaq idea tops our watchlist Monday:  Jaguar Health, Inc. (Nasdaq: JAGX) Jaguar Health, Inc. ("Jaguar") is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. And based on 5 key potential catalysts, (Nasdaq: JAGX) is all over our radar. Check them out: #1. With A Float This Low, The Potential For Heightened Volatility Could Be Significant. #2. The Company Completes A Key Trial With Topline Results Expected Within A Month. #3. A Net Revenue Increase From Q3 To Q4 2025 Shows Momentum Could Be Building. #4. A Strengthened Balance Sheet Highlights The Company's Strategic Focus On A Crofelemer Global Development Program. #5. Multiple Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing. But more on those in a second... Jaguar Health, Inc., in conjunction with Jaguar family company Napo Pharmaceuticals, Inc. (“Napo”), develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal (“GI”) disease states.  Jaguar family companies Napo and Napo Therapeutics, S.p.A., an Italian corporation Jaguar established in Milan, Italy in 2021, are focused on expanding global crofelemer access and are developing new therapies for orphan and rare GI conditions. Here's How Crofelemer Works Crofelemer is a non-opioid that works differently from other treatments for GI dysfunction: From Tree to Bottle, Crofelemer was discovered through the science of ethnobotany. Mytesi is a Novel, First-in-Class Antisecretory Agent Mytesi is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy (ART). Mytesi has a novel mechanism of action that modulates chloride secretion in the gastrointestinal tract, reducing excessive chloride and accompanying water flow and relieving watery diarrhea. What is Canalevia-CA1? Canalevia-CA1 normalizes fluid flow to reinstate normal function in the GI tract and is an antidiarrheal, enteric-coated tablet for oral administration. It acts locally and it is not absorbed into the blood stream, resulting in a well tolerated and non-opioid drug product. It is naturally and sustainably harvested from the sap of a medicinal tropical plant, the Croton lechleri tree. Jaguar Health's Human Health Product Portfolio Jaguar Health's Animal Health Product Portfolio Estimated Size of Mytesi Target Markets The Company believes the medical need for Mytesi is significant, compelling, and unmet, and that doctors are looking for a drug product with a mechanism of action that is distinct from the options currently available to resolve diarrhea.  A growing percentage of HIV patients have lived with the virus in their guts for 10+ years, often causing gut enteropathy and chronic or chronic episodic diarrhea. According to data from the U.S. Centers for Disease Control and Prevention, it was estimated that by 2020 more than 70% of Americans with HIV were 50 and older and had lived with HIV for more than 10 years Discover Key JAGX Company Details And Sources Here: And More: JAGX Website. JAGX Presentation. JAGX Form 10-K. ----- And mentioned earlier in the report, (Nasdaq: JAGX) has several potential catalysts on our radar. Take a look: #1. JAGX Potential Catalyst - With A Float This Low, The Potential For Heightened Volatility Could Be Significant. According to info from the Yahoo Finance website, JAGX has a fairly low float. The website reports this profile to have roughly 12.04Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If the company provides positive news in the first half of 2026, could it help provide a breakout spark when paired with this volatility potential? ----- #2. JAGX Potential Catalyst - The Company Completes A Key Trial With Topline Results Expected Within A Month. Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs Topline results expected within a month and may complement positive results of a study of crofelemer for treatment of cancer therapy-induced diarrhea (CTD) in dogs receiving neratinib - a targeted tyrosine kinase inhibitor (TKI) SAN FRANCISCO, CA / ACCESS Newswire / April 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the Company has completed the company's ongoing effectiveness study of crofelemer delayed-release tablets for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Crofelemer, under the name Canalevia-CA1, is currently conditionally approved for the sole indication of treating CID in dogs. The approval for Canalevia CA-1 will expire on December 21, 2026. "We're very pleased that enrollment has concluded for this study, which is being undertaken at veterinary oncology clinics around the US. The FDA granted renewal of the conditional approval for Canalevia-CA1 for a fifth and final year, through December 21, 2026, for the treatment of CID in dogs. In order to receive a full veterinary drug approval for the indication of CID beyond Dec. 21, 2026, Jaguar must complete and file a successful effectiveness study," said Dr. Michael Guy, D.V.M., M.S., Ph.D., Jaguar's Vice President of Preclinical and Nonclinical Studies. In the second quarter of 2026 Jaguar plans to submit and file the results of the company's effectiveness study and the positive results of a study of crofelemer delayed-release tablets for treatment of CTD in dogs receiving neratinib - a targeted tyrosine kinase inhibitor (TKI) chemotherapy agent. "The 28-day study in dogs receiving neratinib was designed to evaluate the scientific rationale for the use of crofelemer tablets in reducing the severity and incidence of diarrhea in cancer patients receiving neratinib, a targeted therapy known to cause significant diarrhea," said Dr. Guy. "The study demonstrated that crofelemer dosing resulted in a 30% reduction in the incidence and severity of diarrhea in participating dogs, which was statistically significant." ... Read the full article here. ----- #3. JAGX Potential Catalyst - A Net Revenue Increase From Q3 To Q4 2025 Shows Momentum Could Be Building. Jaguar Health Reports 2025 Financials Net revenue increase of 5% in Q4 2025 vs. Q3 2025 Jaguar received an up-front payment of $16Mn of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi and Canalevia-CA1 - Jaguar's commercialized crofelemer drugs - with an additional $2Mn due upon completion of post-closing conditions; and has received $3.0 of up to $20Mn in milestone payments and other future payments Agreement with Future Pak is fully aligned with Jaguar's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure indications moving forward ... SAN FRANCISCO, CA / ACCESS Newswire / April 7, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported its consolidated fourth-quarter 2025 financial results. 2025 FOURTH QUARTER COMPANY FINANCIAL RESULTS: Net Revenue: The total net revenue for the Company's prescription products (Mytesi®, Gelclair®, and Canalevia®-CA1), non-prescription products, and license revenue was approximately $3.2Mn in the fourth quarter of 2025, representing an increase of 5% over the total net revenue in the third quarter of 2025, which totaled approximately $3.1Mn... Read the full article here. ----- #4. JAGX Potential Catalyst - A Strengthened Balance Sheet Highlights The Company's Strategic Focus On A Crofelemer Global Development Program. Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants Strengthening balance sheet and capitalization is a key Jaguar priority Company continues its sharp, strategic focus on global development program for crofelemer for rare-disease intestinal failure indications SAN FRANCISCO, CA / ACCESS Newswire / March 9, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that the Company has strengthened its balance sheet by restructuring and reducing its royalty obligations and debt held by affiliates of Chicago Venture Partners L.P., including the extinguishment of 48,212 warrants. The restructuring consisted of an initial reduction of approximately 10% (amounting to a reduction of approximately $3Mn) of royalty obligations and debt; extending the maturity date by three years for a secured revolving line of credit for approximately $7Mn put in place in November 2025; and ensuring that there are no maturity dates before July 2026 for any debt held by affiliates of Chicago Venture Partners L.P. "We are very pleased to have completed this debt restructuring, and we plan to pursue additional potential opportunities to further restructure and reduce debt over the coming months in agreement with the debt holder," said Lisa Conte, Jaguar's founder, president, and CEO. "Strengthening Jaguar's balance sheet and capitalization is a key priority. Operationally, we continue to sharply focus on our ongoing global development program for our crofelemer powder-for-oral-solution formulation for rare-disease intestinal failure indications. Our intestinal failure program is expected to continue to provide clinical proof-of-concept milestones and is the subject of business development discussions with the potential to bring in non-dilutive funds from potential licensee partners." Read the full article here. ----- #5. JAGX Potential Catalyst - Multiple Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing. At 4:00PM EST Friday, Barchart was reporting JAGX to possess several oversold leaning technical indicators. These technicals could be signaling a healthy reversal is approaching in the near term. Here's the definition of a "reversal" from Investopedia: "A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart." Here are the technicals to pay close attention to (as of 4:00PM EST Friday): 9-Day Relative Strength Index: 35.53% 14-Day Relative Strength Index: 37.06% When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued. Keep an eye on these technicals closely. ----- (Nasdaq: JAGX) Recap - 5 Potential Catalysts Pin This Idea To Monday's Radar #1. With A Float This Low, The Potential For Heightened Volatility Could Be Significant. #2. The Company Completes A Key Trial With Topline Results Expected Within A Month. #3. A Net Revenue Increase From Q3 To Q4 2025 Shows Momentum Could Be Building. #4. A Strengthened Balance Sheet Highlights The Company's Strategic Focus On A Crofelemer Global Development Program. #5. Multiple Oversold Leaning Technical Indicators Could Suggest A Healthy Reversal May Be Nearing. ----- Coverage has officially been kicked-off on Jaguar Health, Inc. (Nasdaq: JAGX). Be on the watch for updates coming your way soon. Keep your eyes peeled. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 04/13/2026 and ending on 04/13/2026 to publicly disseminate information about (JAGX:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named RazorPitch Inc. who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (JAGX:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/jagx-evac0/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice